Cart summary

You have no items in your shopping cart.

Levosimendan

SKU: orb1226334

Description

Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC), provides treatment for heart failure.(In Vitro):Levosimendan (OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan (OR1259) is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan (OR1259) has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy. The cardiovascular effects of Levosimendan (OR1259) are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators. Levosimendan (OR1259) might reduce mortality in cardiac surgery and cardiology settings of adult patients.

Images & Validation

Key Properties

CAS Number141505-33-1
MW280.28
Purity>98% (HPLC)
FormulaC14H12N6O
SMILESCC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N
TargetCarbonic Anhydrase
SolubilityDMSO: 56 mg/mL (199.8 mM)

Bioactivity

In Vitro
Levosimendan (OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan (OR1259) is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan (OR1259) has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy. The cardiovascular effects of Levosimendan (OR1259) are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators. Levosimendan (OR1259) might reduce mortality in cardiac surgery and cardiology settings of adult patients.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

OR 1259 | Simdax | (R)-Simendan

Similar Products

  • Levosimendan [orb1305351]

    99.70%

    141505-33-1

    280.28

    C14H12N6O

    25 mg, 50 mg, 100 mg, 500 mg, 1 ml x 10 mM (in DMSO)
  • OR-1896 [orb1708975]

    99.51% (May vary between batches)

    220246-81-1

    245.28

    C13H15N3O2

    5 mg, 100 mg, 1 mg, 25 mg, 1 ml x 10 mM (in DMSO), 10 mg, 200 mg, 50 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Levosimendan (orb1226334)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

25 mg
$ 70.00
50 mg
$ 90.00
100 mg
$ 100.00
200 mg
$ 150.00
500 mg
$ 310.00